Skip to main content
. 2022 Jan 25;57(3):384–391. doi: 10.1097/SHK.0000000000001910

Table 2.

Differential treatment response on VANISH and Burn trials

Immune-adaptive prevalent (IA-P) Immune-innate prevalent (IN-P)
Hydrocortisone Placebo Hydrocortisone Placebo Interaction P
VANISH TRIAL
 n 30 34 28 25
 28-day mortality (%) 43.3 14.7 32.1 40 0.028
BURN trial
 n 7 8 8 7
 28-day mortality (%) 57.1 0.0 25 28.6 0.99